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Abstract 
Objective: Although current guidelines around the world recommend using absolute 
risk (AR) thresholds to decide whether cardiovascular disease (CVD) risk should be managed 
with lifestyle or medication, the use of AR in clinical practice is limited. The aim of this study 
was to explore the factors that influence general practitioner (GP) and patient decision making 
about CVD risk management, including the role of risk perception.  
Methods: Qualitative descriptive study involving semi-structured interviews with 25 
GPs and 38 patients in Australia in 2011-2012. Transcribed audio-recordings were 
thematically coded and a Framework Analysis method was used.  
Results: GPs rarely mentioned AR thresholds, but were influenced by their subjective 
perception of the patient’s risk and motivation, and their own attitudes towards prevention, 
including concerns about medication side effects and the efficacy of lifestyle change. Patients 
were influenced by individual risk factors, their own motivation to change lifestyle, and 
attitudes towards medication: initially negative, but this improved if medication was more 
effective than lifestyle. High perceived risk led to medication being recommended by GPs and 
accepted by patients, but this was not necessarily based on AR. Patient perceptions of high 
risk also increased motivation to change lifestyle, particularly if they were resistant to the idea 
of taking medication. 
Conclusions: Perceived risk, motivation and attitudes appeared to be more 
important than AR thresholds in this study. CVD risk management guidelines could 
be more useful if they include strategies to help GPs consider patients' risk 
perception, motivation and attitudes as well as evidence-based recommendations. 
Keywords: primary care, cardiovascular disease, prevention, decision 
making, risk appraisals 
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How do General Practitioners and patients make decisions about cardiovascular 
disease risk? 
Current guidelines for cardiovascular disease (CVD) prevention recommend absolute 
risk (AR) assessment to guide the use of preventive medication (Ferket et al., 2010). One of 
the most commonly used models is the Framingham risk equation, using age, gender, 
smoking, diabetes, systolic blood pressure and cholesterol ratio to estimate the risk of a 
cardiovascular event over the next 5 or 10 years (Anderson, Odell, Wilson, & Kannel, 1991; 
D'Agostino et al., 2008). Cholesterol and blood pressure lowering medication are 
recommended for high risk (5 year AR greater than 15%), or for moderate risk (between 10-
15%) with additional risk factors or no improvement after 3-6 months of lifestyle change. 
Lifestyle advice is recommended for all patients, with additional support (such as referral to 
external services) for moderate risk and follow-up for high risk (National Vascular Disease 
Prevention Alliance (NVDPA), 2009, 2012).  
A systematic review suggests that the AR approach to CVD prevention may improve 
the clinical management of patients compared to treating blood pressure and cholesterol as 
separate risk factors (Sheridan & Crespo, 2008). However, research across  the United 
Kingdom, Australia, Europe, North America and South America has shown that many GPs do 
not use AR consistently for CVD risk assessment and treatment decision making (Graham, 
Stewart, Hertog, & Cardiovascular Round Table Task Force, 2006; Heeley et al., 2010; Pound 
et al., 2005; Sposito et al., 2009; Webster et al., 2009). This may result in over-treatment of 
patients with isolated risk factors who are at low to moderate overall risk, and under-treatment 
of patients with low or moderately elevated individual risk factors but high overall risk 
(Doust, Sanders, Shaw, & Glasziou, 2012; Heeley et al., 2010).  
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So how do GPs and patients make treatment decisions if they are not using AR 
thresholds? The shared decision making view that patients should be fully informed about 
evidence-based recommendations and involved in decisions about their health has been 
supported by health policy and consumer group initiatives internationally and in Australia, 
indicating that both GP and patient perspectives are important (McCaffery et al., 2011; Politi, 
Wolin, & Legare, 2013). However, the AR guidelines are focused on evidence-based 
recommendations rather than patient involvement in decision making (NVDPA, 2009, 2012). 
GP decision making about CVD-related medication has traditionally been focused on 
individual risk factors, with blood pressure and cholesterol treated separately (NVDPA, 
2009). Research on GP attitudes towards AR suggests that this is still the default approach for 
many GPs (Heeley et al., 2010; Hobbs, Jukema, Da Silva, McCormack, & Catapano, 2010; 
Torley, Zwar, Comino, & Harris, 2005). From the patient perspective, reviews have found 
that resistance to taking medications is common, adherence to prescribed medication is low, 
and interventions to improve this are often unsuccessful (Burke, Dunbar-Jacob, & Hill, 1997; 
Haynes, Ackloo, Sahota, McDonald, & Yao, 2008; Pound et al., 2005). Lifestyle modification 
is also a significant challenge, with 194 barriers identified in a recent qualitative review of 
factors affecting lifestyle change for patients at high risk of CVD (Murray, Honey, Hill, 
Craigs, & House, 2012). A systematic review of lifestyle interventions in primary care found 
that only 56% of studies reported a significant effect on patient outcomes (Noordman, van der 
Weijden, & van Dulmen, 2012). Behavioural counselling, motivational interviewing, 
education and advice can have an effect on patient outcomes, but the underlying mechanisms 
and acceptability to GPs and patients remain unclear (Noordman et al., 2012).  
Health behaviour models such as the extended parallel process model suggest that the 
decision to undertake risk-reduction behaviours depends on the interaction between risk 
appraisals and coping appraisals (Sheeran, Harris, & Epton, 2013; Witte, 1992). Risk 
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appraisals include: 1) risk perception (e.g. perceived chance of having a heart attack), 2) 
anticipatory emotions about the disease or health threat (e.g. worry about heart attack), 3) 
anticipated emotions if the risk occurs (e.g. regretting lack of medication adherence after a 
heart attack), and 4) perceived severity of the risk (e.g. dying from a heart attack).  Coping 
appraisals include: 1) self efficacy (e.g. perceived ability to reduce risk through lifestyle 
change), 2) response efficacy (e.g. perceived effectiveness of medication), and 3) response 
cost of the risk-reducing behaviour (e.g. medication side effects). This idea has recently been 
supported by an extensive meta-analysis of experimental studies, which showed that health-
related intentions and behaviours are influenced by both risk and coping appraisals, and that 
interventions have the largest effects when both aspects are targeted (Sheeran et al., 2013). 
Although guidelines are based on AR thresholds to determine whether lifestyle or 
medication should be used to manage CVD risk, research suggests that their influence is 
limited. Since little is known about how such decisions are being made in practice, this study 
used a qualitative method to explore the factors that influence both GP and patient decision 
making about CVD risk management, including the role of risk perception. 
Method 
Design 
 A qualitative descriptive study involving semi-structured interviews with 25 GPs and 
38 patients in New South Wales, Australia in 2011-2012.  
Participants 
Participants were purposively selected to cover a range of characteristics known to 
influence CVD risk management (Christian, Mills, Simpson, & Mosca, 2006; Doroodchi et 
al., 2008; Pound et al., 2005; Schmittdiel et al., 2009). For GPs this included gender, age and 
years of GP practice). For patients this included gender, age, and CVD medication use. See 
Tables 1 and 2. 
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Recruitment 
GPs were sent invitation letters through 8 Divisions of General Practice in New South 
Wales, Australia. Participating GPs invited up to 10 patients aged 35-74 years with at least 
one CVD risk factor. GPs were reimbursed $100 for their interview time and $5 per invited 
patient to cover administrative costs. Patients did not receive payment. Fifty-seven GPs and 
49 patients returned expression of interest forms, of which 25 GPs and 38 patients were 
enrolled into the study. Analyses suggested saturation of key themes so no further recruitment 
was conducted (Bowen, 2008). Ethics approval was obtained through the Sydney Local 
Health District. 
Data Collection 
Semi-structured interview schedules were developed by the research team, piloted 
with a convenience sample of GPs and patients, and revised to improve question clarity. The 
interview schedules covered CVD risk assessment, management and communication (see 
Appendix A and B). Findings on risk assessment (Bonner et al., 2013) and risk 
communication (in preparation) will be reported separately to enable a sufficiently detailed 
description of our findings. Participants signed a consent form before being interviewed in 
person or by telephone. Audio-recordings were transcribed verbatim. Two authors trained in 
public health qualitative methods (CB, SM) conducted interviews between October 2011-May 
2012 for GPs and February-August 2012 for patients. 
Analysis 
The research reflects a subtle realist approach, and a Framework Analysis method was 
used to ensure rigour (Ritchie, Spencer, & O’Connor, 2003). This is a matrix-based method of 
thematic analysis involving five steps: 1) familiarisation with the data - three researchers read 
a sample of interview transcripts and discussed emerging themes;  2) creating a thematic 
framework - a themes list was developed and discussed with all authors, and a framework was 
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created with participants as rows and themes as columns in a series of charts; 3) indexing - the 
remaining transcripts were coded according to the framework, with any new themes discussed 
and added to the framework; 4) charting - themes and supporting quotes from each transcript 
were independently summarised in the framework by two researchers, with any disagreement 
resolved through discussion of the best representation of the data, with reference back to the 
original transcripts; 5) mapping and interpretation - to identify overarching themes and 
relationships, the synthesised data were examined within and across themes and participants, 
and discussed with all authors. This process was conducted independently for the GP and 
patient datasets, with the final findings only brought together for comparison at the end. 
Qualitative software was not used for this study. Instead, researchers independently coded 
themes using the comments function in Microsoft Word (2010), wrote a summary for each 
transcript, then summarised the data in the form of a Framework using Microsoft Excel 
(2010), with overarching themes as separate spreadsheets, subthemes as columns, and 
participants as rows. Each step of the Framework Analysis process was carefully followed 
and documented (Ritchie, Spencer, & O’Connor, 2003). Methodological rigour was addressed 
by: repeated coding of transcripts by different team members to ensure a comprehensive 
themes list and framework was achieved; an iterative process of constant comparison between 
the existing framework and new data; detailed documentation of the analysis process; and 
discussion of emerging and final themes with all authors, including an experienced qualitative 
researcher and two academic GPs (Barbour, 2001).  
Results 
Three main themes were identified: risk perception, motivation to change lifestyle, and 
attitudes towards preventive medication. Supporting quotes from participants for each theme 
are provided in Table 3. 
Theme 1: Perceived risk 
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GP perceptions of risk. The decision to recommend medication for ‘high risk’ 
patients was influenced by AR for some GPs, but the 15% threshold for high risk used in the 
guidelines was rarely mentioned. GPs who assessed AR were willing to prescribe medication 
for lower individual risk factors to reduce high AR. Conversely, when AR was not 
considered, GPs were willing to prescribe medication for individual risk factors in presented 
cases where the AR was actually low. The need for medication appeared to be clearer when 
lifestyle change was ineffective or there were multiple risk factors, but the amount of time 
allowed for lifestyle change before medication varied widely.   
Patient perceptions of risk. Most patients were unaware of their AR. Perceptions of 
high risk increased motivation for lifestyle change and acceptance of medication, and were 
based on having consistently elevated, increasing, or multiple risk factors, rather than their 
overall risk of a heart attack or stroke. Some patients were aware of the concept of AR, but in 
one case this led a patient who met the guidelines criteria for cholesterol medication to 
incorrectly believe that her overall risk of a heart attack or stroke was low. In this case, the 
perception of lower risk led to her refusing to take the medication recommended by her GP.  
Theme 2: Motivation to change lifestyle 
GP perceptions of motivation. GPs perceived some patients to be very motivated, in 
which case GPs were willing to give them more time before suggesting medication. Many 
GPs reported patient resistance to the idea of taking medication for CVD risk when they had 
no symptoms, and some described using this resistance to motivate lifestyle change. 
However, not all patients could achieve sufficient lifestyle change to avoid medication, in 
which case a period of lifestyle change was sometimes used to help them to get used to the 
idea. This was reported to improve high risk patients' acceptance of the need for medication if 
there was no improvement within a few months. In contrast, some patients were perceived to 
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be unmotivated to make lifestyle changes, preferring the 'instant cure' of a 'magic pill'. For 
these patients GPs would sometimes prescribe medication at an earlier stage.  
Patient motivation. For patients not taking medication, lifestyle change was 
facilitated if the GP’s advice confirmed existing beliefs about the benefits of this. Motivation 
appeared to be increased by experiencing reduced risk factor levels after making changes. 
Conversely, the experience of lifestyle change not making a difference increased acceptance 
of the future need for medication. 
For patients taking medication, lifestyle management was facilitated by beliefs about 
its benefits in addition to medication, for CVD risk or more general health. Some patients 
taking medication were simply unwilling to change their lifestyle or found it too difficult, so 
medication was considered an easier option. However, many had tried lifestyle change before 
medication but found it to be ineffective for reducing CVD risk, or attributed their risk to 
genetics. This increased acceptance of medication.  
Patients found lifestyle change easier when GPs adapted recommendations to the 
patient's specific situation, and were supportive of patients' ability to change lifestyle and 
avoid medication. On the other hand, some GPs convinced patients to take medication or 
normalised medication as the only option.  
Theme 3: Attitudes towards preventive medication 
GP attitudes. Overall, most GPs had a preference for trying lifestyle change before 
medication, even for high risk patients, and some were reluctant to prescribe preventive 
medication at all. Reasons for this included patient resistance to medication if not given an 
opportunity to try lifestyle first, GP preference to focus on lifestyle change, and ethical 
concerns about giving medication to asymptomatic patients if they weren't willing to try 
changing their lifestyle.  
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Other GPs were much less positive about lifestyle approaches, viewing it as difficult 
and often ineffective. These GPs appeared to be less willing to spend a lot of time addressing 
lifestyle unless the patient was very motivated. 
Patient attitudes. For many patients, avoiding medication provided strong motivation 
for changing lifestyle due to a general aversion to medication, feeling too young to need 
medication, and concerns about the harms of medication. Other patients accepted the 
possibility that they would need medication in future and were happy to trust their GP's 
advice or request medication in order to prevent a CVD event. 
For patients taking medication, negative attitudes to medication were influenced by 
experienced side effects, perceived harms, and preference for ‘natural’ remedies, and many 
were motivated to change their lifestyle by a desire to stop or reduce medication. Several of 
these patients described trial periods without medication, during which they were highly 
motivated to achieve a healthy lifestyle to 'prove' that they did not need to go back on 
preventive medication.  
Positive attitudes to medication were evident amongst patients already taking them, 
which motivated adherence to recommended medication. Although resistance to medication 
was a common first reaction, many patients had come to view medication as a positive way to 
control risk and enable an active lifestyle. Awareness of the benefits of medication was 
reinforced through research, media, friends, family, trust in their GP's advice, and trial 
periods off medication. Other patients just accepted it as part of their daily routine or a 
normal consequence of ageing.  
Relationships between themes 
Three key relationships between perceived risk, motivation to change lifestyle, and 
attitudes towards preventive medication were identified though Framework Analysis: higher 
perceived risk by GPs was required before medication was recommended, whether this was 
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based on AR or a more subjective assessment of overall risk; higher perceived risk by the 
patient could increase acceptance of recommended medication and/or increase motivation to 
change lifestyle; and resistance to medication by the patient led to higher motivation to 
change lifestyle. The arrows in Figure 1 show these relationships between the main themes.  
Discussion 
Our interviews suggest that decision making about CVD risk management is 
influenced by: GP and patient perceptions of risk, which may or may not include a formal 
assessment of AR by the GP; patient motivation to change lifestyle; and attitudes towards 
preventive medication; rather than AR thresholds. These factors appeared to influence 
decision making about CVD risk management for both GPs and patients, although they did 
not always interpret them in the same way: patients’ risk perception may be lower or higher 
than the GPs’ assessment, patients may be unmotivated to change their lifestyle even when 
GPs make a concerted effort to help them achieve this, and high risk patients may choose not 
to take medication recommended by the GP due to negative attitudes towards this approach. 
Our qualitative findings support the view that both risk appraisals and coping 
appraisals are important in decision making about CVD risk management (Sheeran et al., 
2013; Witte, 1992). Patients and GPs both described the importance of risk perception, but 
patients generally focused on individual risk factors, while GPs were more aware of the 
overall risk of heart attack and stroke, and the consequences of such events (perceived 
severity). Motivation to change lifestyle was considered by both GPs and patients, as reducing 
risk without medication (response efficacy) was perceived to require considerable effort from 
the patient (self efficacy). Medication was resisted by most patients at first due to concerns 
about side effects (response cost), unless their risk was perceived as high and medication was 
viewed as more effective than lifestyle change (risk perception and response efficacy). Some 
GPs and patients mentioned worry about CVD risk factors (anticipatory emotions), and how 
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they would feel if a CVD event did occur (anticipated regret), but emotions were not 
identified as a major decision making factor in our analysis. Table 4 provides a summary of 
how the findings relate to the concepts of risk and coping appraisal. This conceptual model 
places the findings in the broader context of risk-related behaviour change, but was 
considered after the Framework Analysis process had been completed to avoid biasing the 
results. 
Both GPs and patients were more influenced by subjective perceptions of CVD risk 
than objective absolute risk assessment, and these perceptions did not always match. An 
objective risk assessment is required before an evidence-based recommendation can be 
provided by the GP, to enable the patient to make an informed choice about management 
options together with their GP (Politi et al., 2013). This highlights the importance of 
evidence-based risk assessment by GPs, and communication of this to the patient. Previous 
research has found that GPs do not estimate overall CVD risk accurately when AR is not 
objectively calculated, which may lead to over- or under-treatment (Doust et al., 2012; Heeley 
et al., 2010). Patients may perceive CVD risk differently to GPs, often focusing on particular 
risk factors that may or may not reflect their overall CVD risk (Damman & Timmermans, 
2012). Calculating AR may therefore correct misperceptions of risk by both the patient and 
the GP, and enable shared decision making. The risk communication literature has not 
identified a single ‘best’ way of communicating such risks to patients, but the International 
Patient Decision Aid Standards (IPDAS) suggest using equivalent numerical, verbal and 
graphical formats to help explain probabilities to patients with different levels of literacy 
(Trevena et al., 2013). Accessible AR assessment tools that incorporate patient 
communication strategies, including the role of specific risk factors, may also improve the 
accuracy of, and agreement between, GP and patient risk perceptions (Peiris et al., 2012). 
However, even if AR is assessed and communicated effectively, other factors may prevent 
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GPs from using an AR-based approach to management. High risk patients over the 15% 
threshold may decline medication if they don't think their risk is high enough to justify the 
potential side effects (Pound et al., 2005). Lower risk patients may be unable or unwilling to 
change their lifestyle (Murray et al., 2012), and may request medication if they think that is an 
easier or more effective option. This is consistent with a study showing that GPs in the UK 
prioritise patient-centred care over prescribing guidelines when these two aims are 
incompatible (Solomon, Raynor, Knapp, & Atkin, 2012).  
CVD risk management guidelines could be more useful if they include strategies to 
help GPs consider patients' risk perception, motivation and attitudes as well as evidence-based 
recommendations (van der Weijden et al., 2010). For example, the guidelines indicate that 
high risk patients should take medication and change their lifestyle, but do not describe what 
to do if the patient is unwilling to do this. If the patient misunderstands their level of risk or 
has just seen a negative article about medication in the media, an educational approach may 
be sufficient to address the issue. If the patient is highly motivated to change their lifestyle 
and avoid medication, supporting their stated preferences for a period of time may be a useful 
strategy to either achieve sufficient lifestyle change to reduce risk to a lower level, or increase 
acceptance of medication if lifestyle is shown to be ineffective. If the GP is finding it difficult 
to motivate the patient to change their lifestyle, referral to external services could be 
considered as an explicit option in the guidelines. 
The strengths of this study include a heterogeneous sample with a wide range of 
characteristics, and comparison of themes between GPs and patients. The sampling strategy 
aimed to maximise the range of experiences and views rather than being representative of the 
general population. Ethnicity data was not specifically collected, but GP and patient 
transcripts include references to Chinese, Indian, Eastern European, Anglo-Saxon and 
Hispanic ethnicities/languages. However, no Aboriginal or Torres Strait Islander participants 
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were recruited, which limits the relevance of the findings for the Australian context. Future 
research could investigate differences between GP and patient perceptions more directly by 
comparing GP-patient dyads. 
This study investigated both GP and patient perspectives on decision 
making about CVD risk management, and found that perceived risk, motivation 
and attitudes appeared to be more important than AR thresholds across GPs and 
patients. Even when AR assessment is used, management guidelines may not be 
followed due to the influence of motivation and attitudes. CVD risk management 
could be improved through clearer guidelines that acknowledge the role of patient 
preferences and the difference between perceived risk and calculated risk.
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Table 1 
GP participant characteristics (n=25) 
Characteristic Category n 
Gender Female 15 
 Male 10 
Age (years) <40 6 
 40-49 8 
 50-59 7 
 60+ 4 
Years of practice <10 5 
 10-19 6 
 20-29 9 
 30+ 5 
GP role in practice Registrar/in training 1 
 Contractor/sessional/retainer/salaried 14 
 Partner/principal 10 
Medical record system Electronic only 23 
 Electronic and paper 1 
 Paper only 1 
Number of GPs in practice 1-5 10 
 6-10 13 
 11-15 2 
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Table 2 
Patient participant characteristics (n=38) 
Characteristic Category n  
Gender Female 21 
 Male 17 
Age (years) 35-39 3 
 40-49 2 
 50-59 15 
 60-69 14 
 70-74 4 
Highest education Year 10 or below 7 
 Year 12 3 
 Technical Diploma 10 
 Undergraduate university degree 8 
 Postgraduate university degree 10 
Marital status Never married 7 
 De facto 7 
 Married 16 
 Divorced 5 
 Widowed 3 
Country of birth Australia 23 
 United Kingdom 5 
 Europe 3 
 North America 3 
 Asia 2 
 New Zealand 2 
CVD medication use Medication not recommended 15 
 Not taking recommended medication 2 
 Taking preventive medication 16 
 Taking medication after CVD event 5 
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Table 3 
Supporting quotes from GPs (shaded) and patients by theme 
Theme 1: Perceived risk 
Higher risk 
perception 
increases 
preference for 
medication 
"If say a patient is obese or they have a very strong family history...I would 
probably have a lower threshold starting medication."  (GP) 
Lower risk 
perception 
decreases 
preference for 
medication 
"You have to look at heart disease in a total package. And I don’t have 
enough of the total package to have a heart attack. When I start having 
more of that package then it’s, you know, I’ve got to...do what I’m told. But 
at the moment they are prepared for me to think through this... I know 
mine’s really high (cholesterol). I know it’s genetic. But it...couldn’t be 
depositing much plaque down because my blood pressure’s good." (patient 
not taking recommended medication) 
Theme 2: Motivation to change lifestyle 
Lifestyle 
change 
motivated by 
avoiding 
medication 
"Once you’ve explained to them their risk most of them understand very 
well where they're going and what they need to do and they always, most 
of them are pretty keen on the lifestyle modification. Doc if I do that do you 
think it will come down, I don't have to take a tablet." (GP) 
Period of 
lifestyle 
change used 
to increase 
medication 
acceptance 
"He may not be willing to start any medication...even if I give him the 
script he is not going to take it... in that case I have to tell him that 'look try 
all these changes, come back in 3 months or 2 months'...when he comes 
back and we see that the levels haven’t gone down...he would be more 
amenable to the idea of starting medication." (GP) 
Lifestyle 
change seen 
as too 
difficult 
"They all want a pill (laughter) for everything and that's the main 
challenge we find...not many patients are willing to change their lifestyle 
unfortunately...they want the easy way out. A pill for everything."  (GP)  
Belief in 
additional 
benefits of 
lifestyle 
change 
"You cannot do one thing without the other...no use starting those tablets if 
you go overboard with the diet, I mean people say ‘oh it doesn't matter, 
take the tablets I can do anything I like’. That's not true...you have to have 
a good diet as well as taking the tablets. The tablets alone is not going to 
fix everything." (patient taking medication) 
Lifestyle 
change 
proven to be 
ineffective 
“For a long time I avoided doing it, didn't want to do it and tried it just to 
go through all the lifestyle...sort of good eating and everything but it just 
didn't budge so eventually I agreed to go on medication... I put it off...for a 
long time and then realised no matter what I did it just, it was high every 
time.” (patient taking medication) 
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Lifestyle 
change not 
discussed as 
an option 
"You hear lots of nasty stories about side effects and things not working 
well together but she reassured me that what I was on was sort of fairly 
standard generic medication and I didn't have to worry about those sorts 
of things...at the time the solution was medication. I have since changed 
doctors...and have lost 18 kilos in that time and reduced my blood pressure 
medication...less than impressed that that conversation didn't happen when 
I was first diagnosed." (patient taking medication) 
Theme 3: Attitudes towards preventive medication 
Preference to 
focus on 
lifestyle 
change 
“From every point of view, from patient care, cost...if you can make the 
changes which have the least amount of cost to everyone then I think that's 
usually lifestyle. So that's usually the way that I start with and then use 
medication if we’re not getting there." (GP)  
Ethical 
concerns 
about giving 
medication 
"The problem with a lot of patients is they don't want to change what they 
do and if...they’re quite often happy to take a tablet and want that to be the 
instant cure and I don't agree with that."  (GP)  
Medication 
viewed as 
easier/more 
effective 
"These things are a lot easier said than done.  So achieving those results 
[through lifestyle change] and bringing blood pressure, bringing the 
cholesterol down, quitting smoking – they are time consuming and 
difficult." (GP) 
Perceived 
harms of 
medication 
"I wouldn’t like to take statins…especially with all the issues going on with 
statins and the FDA [Food and Drug Administration] about looking at the 
diabetes too and all the other issues, liver problems...I try to stay away 
from drugs." (patient not taking medication) 
Perceived 
benefits of 
medication 
"It will put me in a better place by taking medication...I don't want to have 
an ego where I don't want to take medication because of my age, and find 
that I have got problems down the track...I’m quite happy to be directed." 
(patient not taking medication) 
Motivated to 
reduce/stop 
medication to 
avoid side 
effects 
"I am desperately trying to get off them …there are negative effects of the 
medication. So I want to reduce weight...I’m due to go back there and say 
look we want to knock down, halve one of the tablets. The reason I want to 
reduce them or get rid of them is that they do have negative effects on you, 
like a little bit light headiness and so that's one of the pushes to try and get 
off them." (patient taking medication) 
Medication 
accepted as 
normal/part 
of routine 
“I resisted it to start with but I realised if I didn't take it, I could have other 
complications so it didn't really worry me...if I take my tablets…it hasn’t 
interrupted with my lifestyle and…I’ve just accepted it.” (patient taking 
medication) 
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Table 4 
Role of risk and coping appraisals in decision making about CVD risk 
Risk appraisals GP conceptualisation Patient conceptualisation 
Risk perception Mix of overall risk and 
individual risk factors 
Based more on individual risk 
factors, little awareness of absolute 
risk, enhanced after CVD event 
Anticipatory 
emotions 
Conveyed to patients in terms 
of being worried or concerned 
Worry more if experience with 
CVD events (self or family) 
Anticipated emotions Some anticipation of regret if 
fail to prevent CVD event 
Not a main consideration for 
patients 
Perceived severity High awareness of severe 
consequences of CVD risk 
Link between individual risk 
factors, overall risk and CVD 
events not clear, enhanced after 
CVD event 
Coping appraisals GP conceptualisation Patient conceptualisation 
Self-efficacy Perceived as low for lifestyle, 
high for medication 
Perceived as high for both lifestyle 
and medication; increased for 
lifestyle if they want to avoid 
medication 
Response efficacy Perceived as low for lifestyle, 
high for medication 
Perceived as higher for medication 
than lifestyle especially after 
unsuccessful lifestyle change 
Response cost Some concern amongst GPs 
but patient concerns more 
important 
Perceived as very high for 
medication and lower for lifestyle 
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[SEE SEPARATE PPT FILE] 
 
Figure 1. Summary of GP and patient decision making factors identified through Framework 
Analysis. Arrows indicate key relationships between themes.  
 
 
 
 
